Dana-Farber Cancer Institute

https://www.dana-farber.org/

 

Dana-Farber Cancer Institute
T

ASCO® 2023 Insights: "CONTACT-03 Study: Efficacy and Safety of Atezolizumab + Cabozantinib vs. Cabozantinib Alone After Progression With Prior ICI Treatment in mRCC"

By Dana-Farber Cancer Institute FEATURING Toni Choueiri
By Dana-Farber Cancer Institute FEATURING Toni Choueiri
79 views
June 14, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay
ASCO® 2023
22:44
Dana-Farber Cancer Institute

ASCO® 2023 Summary: "RCC Updates From The Recent Trials"

Feat. W. Xu, T. Choueiri
20:05
Dana-Farber Cancer Institute

ASCO® 2023 Summary: "Prostate Cancer Updates From The Recent Tr…

Feat. J. Berchuck, M. Taplin
18:57
Dana-Farber Cancer Institute

ASCO® 2023 Summary: "Bladder Cancer Updates From The Recent Tri…

Feat. C. Mantia, J. Bellmunt
23:16
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Optimizing Therapy Selection for Patients…

Feat. B. McGregor
12:04
Insights from 2023 ASCO® Annual Meeting

INSIGHT Study - Ripretinib vs. Sunitinib in Patients With Advanced G…

Feat. S. George
06:11
ecancer

ASCO® 2023 Insights: "Key Head & Neck Data"

Feat. G. Hanna
01:25
Dana-Farber Cancer Institute

ASCO® 2023 Insights: "INDIGO Trial on Vorasidenib vs. Placebo i…

Feat. P. Wen
01:41
Dana-Farber Cancer Institute

ASCO® 2023 Insights: "Dose Expansion Results of the Bifunctiona…

Feat. G. Hanna
02:27
Dana-Farber Cancer Institute

ASCO® 2023 Insights: "Initial Chemo for Locally Advanced & …

Feat. J. Luo
01:51
Dana-Farber Cancer Institute

ASCO® 2023 Insights: "Effect of a Telephone-Based Weight Loss I…

Feat. J. Ligibel
02:25
Dana-Farber Cancer Institute

ASCO® 2023 Insights: "Prognosis & Trends in Adjuvant Chemo …

Feat. P. Tarantino
01:46
Dana-Farber Cancer Institute

ASCO® 2023 Insights: "TROPiCS-02 Final OS Analysis of Sacituzum…

Feat. S. Tolaney
05:00
ecancer

ASCO® 2023 Insights: "Phase 3 CONTACT-03 Study - Efficacy &…

Feat. T. Choueiri
02:12
Dana-Farber Cancer Institute

ASCO® 2023 Insights: "CONTACT-03 Study: Efficacy and Safety of …

Feat. T. Choueiri
02:32
Dana-Farber Cancer Institute

ASCO® 2023 Insights: "Prognostic Impact of PSA Nadir (n)≥0.1ng/…

Feat. P. Ravi
07:12
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Association of Host Immune Signatures Wit…

Feat. E. Saad
09:44
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Long-Term Safety of Avelumab 1L Maintenan…

Feat. J. Bellmunt
09:12
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Cabozantinib, Nivolumab, and Ipilimumab f…

Feat. B. McGregor